Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 321 participants.

Also called NCT03062319

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 321 participants (enrolled count) (from the registry)
Sponsor
National Hospital Organization Osaka National Hospital (from the registry)
Registry
  • NCT NCT03062319
Other papers using this trial's data
  • Optimal Antithrombotics for Ischemic Stroke and Concurrent Atrial Fibrillation and Atherosclerosis: A Randomized Clinical Trial JAMA neurology, 2025-12-01 DOI, PubMed 41051787, PMC12501853 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03062319. Randomized; no masking; primary purpose prevention. Start 2017-04-06 (actual); primary completion 2023-07-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis
Acronym
ATIS-NVAF
Condition
Atherothrombosis
Intervention (Drug)
Oral Anticoagulant
Intervention (Drug)
Antiplatelet Drug
Lead sponsor
National Hospital Organization Osaka National Hospital (class: other)
Collaborator
Network for Clinical Stroke Trials (class: not stated)
Collaborator
The BMS/Pfizer Japan Thrombosis Investigator Initiated Research Program (class: not stated)

Record details

Record id
cardio:ct-nct03062319
Content hash
370fe4bb52dc92cbfc49a3a6dbb21c088a875a32465d4e071e993bb16b366e02